Goodacre R L, Ali M A, Vanderlinden B, Hamilton J D, Castelli M, Seaton T
Digestion. 1978;17(6):503-8. doi: 10.1159/000198156.
Hemolytic anemia is a well-recognized complication of sulfasalazine treatment. 17 of 40 (43%) patients with inflammatory bowel disease receiving sulfasalazine had evidence of hemolysis as detected by starch gel electrophoresis. Only 47% (8) of patients with hemolysis had Heinz body formation. The hemoglobin was significantly reduced in patients with hemolysis and 53% had a reticulocyte count of greater than 5%. A significant correlation was noted between hemolysis and serum sulfapyridine level, but no correlation was seen with serum sulfasalazine level. There was no significant difference in disease extent or activity in patients with hemolysis compared to those without hemolysis. Hemolysis is not a rare side-effect of sulfasalazine therapy. Heinz body formation is not invariably found in sulfasalazine-induced hemolysis.
溶血性贫血是柳氮磺胺吡啶治疗中一种公认的并发症。在40例接受柳氮磺胺吡啶治疗的炎症性肠病患者中，有17例（43%）经淀粉凝胶电泳检测有溶血证据。溶血患者中只有47%（8例）出现海因茨小体形成。溶血患者的血红蛋白显著降低，53%的患者网织红细胞计数大于5%。溶血与血清磺胺吡啶水平之间存在显著相关性，但与血清柳氮磺胺吡啶水平无相关性。与未发生溶血的患者相比，发生溶血的患者在疾病范围或活动度方面无显著差异。溶血并非柳氮磺胺吡啶治疗的罕见副作用。柳氮磺胺吡啶诱导的溶血并不总是出现海因茨小体形成。
